Hot Trades in Pre-Market US Stocks

Amphenol fell 3.94% in pre-market trading. Based on recent key news:

1. On July 25, weak industrial and automotive demand led to stock price volatility. Analysts are concerned about widespread weakness in the industrial and commercial vehicle markets, with inventory adjustments offsetting growth in the company's high-speed interconnect division, impacting stock prices.

2. On July 25, Amphenol acquired CommScope's mobile network business for $2.1 billion, bringing execution risks and increased debt. Investors are skeptical about the timing of synergies against the backdrop of a cooling global telecommunications market, affecting stock prices.

3. On July 25, the stock price was at a significant premium compared to historical price-to-earnings ratios, with institutional investors shifting to other electronic component manufacturers due to rising yields and macroeconomic uncertainty, leading to a substantial adjustment in stock prices. The electronic components industry is facing macroeconomic pressures.

Taiwan Semiconductor fell 3.58% in pre-market trading. Based on recent key news:

1. On July 28, a magnitude 7.1 earthquake struck Kumamoto, Japan, prompting Taiwan Semiconductor to initiate emergency evacuation procedures at its JASM plant, affecting production operations. Taiwan Semiconductor stated that personnel safety is the top priority, and the plant temporarily halted operations for safety inspections, leading to a drop in stock prices.

2. On July 27, Nomura Securities released a report on the AI semiconductor industry, indicating that Taiwan Semiconductor's revenue and capital expenditure outlook exceeded market expectations, but the stock price fell due to fluctuations in the Philadelphia Semiconductor Index. Nomura maintains a positive outlook for Taiwan Semiconductor in the future.

3. On July 26, the global semiconductor sector experienced a wave correction, with Taiwan Semiconductor raising its full-year capital expenditure and revenue outlook at its earnings call, but the stock price corrected due to technical adjustments and capital rotation. Mega Financial Investment Trust believes this is an excellent opportunity for long-term positioning. Global deleveraging pressures are increasing, and market volatility is intensifying.

Top Gainers in Pre-Market US Stocks

C3is rose 92.48% in pre-market trading. Based on recent key news:

1. On July 27, C3is announced a public offering at a price of $0.52 per unit, expecting total proceeds of approximately $6 million. This move attracted market attention, driving a significant increase in stock prices. Source: Reuters

2. On July 25, C3is executed a 1-for-7 reverse stock split to regain compliance and reported a 358% surge in adjusted net income for the first quarter to $5.5 million. This financial performance boosted investor confidence. Source: Reuters

3. On July 27, C3is entered the US capital market through SEC registration statements and underwriting public offerings, utilizing equity and warrant structures to fund its operations and growth plans. This move further enhanced market expectations for its future development. Source: Reuters The shipping industry has recently performed strongly, with significant capital inflows.

T3 Defense rose 56.70% in pre-market trading. Based on recent key news:

1. On July 24, T3 Defense submitted a SCHEDULE 13D filing, revealing its strategic acquisition plans. The company focuses on acquiring and improving operational businesses, planning to expand its strategic stake through follow-up transactions and close collaboration with management This news has driven optimistic expectations in the market regarding its future growth potential, leading to a significant increase in stock prices. Source: SEC announcement

2. No other important news recently. The market reacted positively to the acquisition plan, driving stock prices up.

Gossamer Bio pre-market rose 43.23%. Based on recent key news:

1. On July 28, Gossamer Bio announced plans to submit a new drug application for seralutinib in September 2026 after a meeting with the FDA. This move boosted stock prices as market optimism regarding drug approval increased. Source: Zhitong Finance

2. On July 27, the company announced the repurchase of global development and commercial rights for seralutinib from Chiesi Group, optimizing its capital structure. This news boosted investor confidence, leading to a rise in stock prices. Source: Zhitong Finance

3. On July 27, shareholders approved the exchange of convertible notes and a reverse stock split, aimed at supporting compliance with Nasdaq's minimum bid requirements. This move improved the company's financial condition, driving stock prices up. Source: Zhitong Finance The biopharmaceutical industry has performed strongly recently, with significant capital inflows